Molecular Targets in Cancer Therapy and Their Impact on Cancer Management

2nd State-of-the-Art Conference
Montreux, Switzerland, February 23–24, 2002

Guest Editor
Axel Ullrich, Martinsried, Germany
Supported by an educational grant from F. Hoffmann-La Roche Ltd, Basel, Switzerland

The opinions and views expressed in this educational supplement are those of the authors and do not necessarily reflect the opinions or recommendations of F. Hoffmann-La Roche Ltd. The articles in this supplement may discuss uses and dosages of Herceptin or other pharmaceutical agents that are not approved by regulatory authorities in Europe and elsewhere. Please consult local prescribing information before using any product.
Contents

Introduction

1 Molecular Targets in Cancer Therapy and Their Impact on Cancer Management
   Ullrich, A. (Martinsried)

6 HER-Targeted Tyrosine-Kinase Inhibitors
   Baselga, J. (Barcelona); Hammond, L.A. (San Antonio, Tex.)

17 Perspectives on Anti-HER Monoclonal Antibodies
   Ranson, M. (Manchester); Sliwkowski, M.X. (San Francisco, Calif.)

25 Current Status of HER2 Testing
   Di Leo, A. (Brussels); Dowsett, M. (London); Horten, B. (New York, N.Y.);
   Penault-Llorca, F. (Clermont-Ferrand)

33 Emerging Technologies for HER2 Testing
   van de Vijver, M. (Amsterdam)

39 What Can We Learn from Herceptin® Trials in Metastatic Breast Cancer?
   Bell, R. (Geelong)

47 The Future of Targeted Therapy: Combining Novel Agents
   Gianni, L. (Milan)

57 Moving Forward: Herceptin® in the Adjuvant Setting
   Tan-Chiu, E. (Plantation, Fla.); Piccart, M. (Brussels)

64 Author Index Vol. 63, Suppl. 1, 2002
64 Subject Index Vol. 63, Suppl. 1, 2002